Reducing Radiation Exposure

The use of cancer radiation therapy and interventional fluoroscopy is expanding rapidly, and medtech start-ups are pioneering innovative technologies to capitalize on the industry-wide movement to reduce radiation exposure and improve outcomes. Profiles of ControlRad Systems, Nanovi, and SoniTrack Systems.

Radiation is both a healer and a killer: it has revolutionized the diagnosis and treatment of human diseases and almost eliminated the need for once-common exploratory surgeries, while at the same time subjecting patients and medical staff to its dangers, which include cancer risk. Its use is growing rapidly: Americans' exposure to medical radiation increased more than sixfold between the 1980s and 2006, according to the National Council on Radiation Protection and Measurements (NCRP). This is largely due to a rapid increase in the use of advanced imaging and treatment technologies such as computed tomography (CT; which alone accounts for 24% of all radiation exposure in the US), nuclear medicine (including lung, heart, bone, and brain scans), radiation therapy for cancer, and interventional fluoroscopy. The latter includes a vast array of common image-guided procedures such as angiographies, angioplasties, and stent implantations, along with more complex (and high-dose) minimally invasive treatments throughout the body such as abdominal aortic aneurysm endograft implantations, vertebroplasty and kyphoplasty in the spine, embolizations in the brain and other areas, cardiac ablation, and a host of others, according to the American College of Radiology (ACR) and the National Cancer Institute (NCI). More than 70 million CT scans, 18 million nuclear medicine procedures, and 17 million interventional fluoroscopy procedures are performed in the US each year, according to the NCRP, and these figures will continue to grow. In fact, interventional procedures are responsible for about 90% of the total radiation exposure in the medical field.

The growing use and increasing complexity of these procedures have been accompanied by public health concerns about the increasing radiation exposure to both patients and health care personnel, and a number of industry players – physicians, technologists, medical physicists, fluoroscopy and radiation therapy equipment manufacturers, and medical and governmental organizations – are implementing strategies to optimize radiation doses and improve safety. Medtech start-ups, such as the three innovators detailed in this issue, are seizing the opportunity to provide add-on solutions to increase safety and efficacy in radiation therapy and fluoroscopy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By 

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.